Should You Buy AbbVie Stock Before April 29?

AbbVie (NYSE: ABBV) is simply a starring drugmaker that investors person travel to trust connected for dependable and accordant results implicit the years. Along the way, it has besides paid and accrued its dividend connected a regular basis. It's been 1 of the amended healthcare stocks to own, and it has astir doubled successful worth successful conscionable 5 years.

This year, it's been disconnected to a pugnacious start, declining by astir 10%. But the institution reports net aboriginal this month, and a beardown show could springiness investors a crushed to load up connected the stock. Should you bargain shares of AbbVie earlier it releases its latest net numbers connected April 29?

Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »

AbbVie has faced immoderate important challenges successful caller years, astir notably with the nonaccomplishment of patent extortion connected its top-selling drug, Humira. The company, however, has shown that it tin proceed increasing amid the mislaid revenue. New drugs Skyrizi and Rinvoq are doing exceptionally well, and AbbVie has bolstered its concern via acquisitions successful caller years. The extremity effect is simply a much diversified healthcare company, and its maturation complaint has been picking up the gait successful caller quarters.

Meanwhile, connected the bottommost line, things look adjacent better. This year, the institution is projecting its adjusted diluted net per stock (EPS) volition beryllium wrong a scope of $13.96 to $14.16, which would beryllium a important summation from 2025, erstwhile its adjusted diluted EPS was $10.00.

AbbVie's banal hasn't been getting overmuch emotion from investors for its beardown results amid adversity. Its apical enactment whitethorn look unimpressive successful caller years, but that's with the institution facing immoderate sizeable challenges related to Humira. A beardown show successful the archetypal 4th of 2026 could beryllium conscionable what the healthcare banal needs to punctual investors of the coagulated concern that it is.

While its valuation looks high, with AbbVie trading astatine a price-to-earnings aggregate of 88, that's mostly owed to the effects of one-time expenses arsenic a effect of acquisitions. Based connected expert expectations of aboriginal earnings, however, it's trading astatine an net aggregate of conscionable 14.

AbbVie's banal is simply a coagulated semipermanent bargain for its maturation opportunities and high-yielding dividend, which presently pays 3.3% (the S&P 500 average is lone 1.2%). And the institution has tripled the complaint of its quarterly payout implicit the past decade. Whether you privation reliable dividend income oregon to instrumentality vantage of its semipermanent maturation potential, AbbVie is simply a coagulated concern you tin bent connected to for years.